Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2013

 

OR

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

for the transition period from            to           

 

Commission file number 1-08323

 

Cigna Corporation

(Exact name of registrant as specified in its charter)

 

Delaware

 

06-1059331

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

900 Cottage Grove Road Bloomfield, Connecticut

 

06002

(Address of principal executive offices)

 

(Zip Code)

(860) 226-6000

Registrant’s telephone number, including area code

(860) 226-6741

Registrant’s facsimile number, including area code

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark

 

YES

 

NO

 

· whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

R

 

o

 

· whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

R

 

o

 

· whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer R

Accelerated filer o

Non-accelerated filer o

Smaller Reporting Company o

 

· whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

 

o

 

 

R

 

As of April 15, 2013,  285,322,450 shares of the issuer’s common stock were outstanding.

 



Table of Contents

 

Cigna Corporation

 

INDEX

 

 

 

 

PART I

FINANCIAL INFORMATION

Page

 

 

 

Item 1.

Financial Statements (Unaudited)

 

 

Consolidated Statements of Income

1

 

Consolidated Statements of Comprehensive Income

2

 

Consolidated Balance Sheets

3

 

Consolidated Statements of Changes in Total Equity

4

 

Consolidated Statements of Cash Flows

5

 

Notes to the Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

42

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

73

Item 4.

Controls and Procedures

74

 

 

 

 

 

 

PART II

OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings

75

Item 1.A.

Risk Factors

76

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

77

Item 4.

Mine Safety Disclosures

77

Item 6.

Exhibits

78

SIGNATURE

79

INDEX TO EXHIBITS

E-1

 

 

As used herein, “Cigna” or the “Company” refers to one or more of Cigna Corporation and its consolidated subsidiaries.

 



Table of Contents

 

 

 

 

 

Part I.   FINANCIAL INFORMATION

 

 

 

 

 

 

Item 1.   FINANCIAL STATEMENTS

 

 

Cigna Corporation

Consolidated Statements of Income

 

 

 

 

Unaudited

 

 

 

Three Months Ended

 

 

 

March 31,

 

(In millions, except per share amounts)

 

2013

 

2012

 

Revenues

 

 

 

 

 

Premiums and fees

 

$

7,314

 

$

6,107

 

Net investment income

 

287

 

288

 

Mail order pharmacy revenues

 

425

 

386

 

Other revenues

 

18

 

(40

)

Realized investment gains (losses):

 

 

 

 

 

Other-than-temporary impairments on fixed maturities, net

 

-

 

(3

)

Other realized investment gains

 

139

 

16

 

Total realized investment gains

 

139

 

13

 

Total revenues

 

8,183

 

6,754

 

Benefits and Expenses

 

 

 

 

 

Global Health Care medical claims expense

 

4,047

 

3,316

 

Other benefit expenses

 

1,862

 

825

 

Mail order pharmacy cost of goods sold

 

344

 

321

 

GMIB fair value (gain)

 

-

 

(67

)

Other operating expenses

 

1,856

 

1,807

 

Total benefits and expenses

 

8,109

 

6,202

 

Income before Income Taxes

 

74

 

552

 

Income taxes (benefits):

 

 

 

 

 

Current

 

(101)

 

135

 

Deferred

 

116

 

46

 

Total income taxes

 

15

 

181

 

Net Income

 

59

 

371

 

Less: Net Income Attributable to Redeemable Noncontrolling Interest

 

2

 

-

 

Shareholders’ Net Income

 

$

57

 

$

371

 

Shareholders’ Net Income Per Share:

 

 

 

 

 

Basic

 

$

0.20

 

$

1.30

 

Diluted

 

$

0.20

 

$

1.28

 

Dividends Declared Per Share

 

$

0.04

 

$

0.04

 

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

 

1



Table of Contents

 

Cigna Corporation

Consolidated Statements of Comprehensive Income

 

 

 

 

Unaudited

 

 

 

Three Months Ended
March 31,

 

(In millions, except per share amounts)

 

2013

 

 

2012

 

Shareholders’ net income

 

$

57

 

 

$

371

 

Shareholders’ other comprehensive income (loss):

 

 

 

 

 

 

Net unrealized appreciation (depreciation) on securities:

 

 

 

 

 

 

Fixed maturities

 

(72)

 

 

23

 

Equity securities

 

2

 

 

1

 

Net unrealized appreciation (depreciation), on securities

 

(70)

 

 

24

 

Net unrealized appreciation (depreciation), derivatives

 

3

 

 

(5)

 

Net translation of foreign currencies

 

(58)

 

 

35

 

Postretirement benefits liability adjustment

 

40

 

 

11

 

Shareholders’ other comprehensive income (loss)

 

(85)

 

 

65

 

Shareholders’ comprehensive income (loss)

 

(28)

 

 

436

 

Comprehensive income (loss) attributable to noncontrolling interest:

 

 

 

 

 

 

Net income attributable to redeemable noncontrolling interest

 

2

 

 

-

 

Other comprehensive (loss) attributable to redeemable noncontrolling interest

 

(3)

 

 

-

 

Total comprehensive income (loss)

 

$

(29)

 

 

$

436

 

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

 

2



Table of Contents

 

Cigna Corporation

Consolidated Balance Sheets

 

 

 

 

Unaudited

 

 

 

As of

 

As of

 

(In millions, except per share amounts)

 

March 31, 2013

 

December 31, 2012

 

Assets

 

 

 

 

 

 

 

 

 

Investments:

 

 

 

 

 

 

 

 

 

Fixed maturities, at fair value (amortized cost, $14,531; $15,481)

 

 

 

$

16,600

 

 

 

$

17,705

 

Equity securities, at fair value (cost, $137; $121)

 

 

 

131

 

 

 

111

 

Commercial mortgage loans

 

 

 

2,811

 

 

 

2,851

 

Policy loans

 

 

 

1,504

 

 

 

1,501

 

Real estate

 

 

 

82

 

 

 

83

 

Other long-term investments

 

 

 

1,249

 

 

 

1,255

 

Short-term investments

 

 

 

122

 

 

 

154

 

Total investments

 

 

 

22,499

 

 

 

23,660

 

Cash and cash equivalents

 

 

 

3,306

 

 

 

2,978

 

Accrued investment income

 

 

 

277

 

 

 

258

 

Premiums, accounts and notes receivable, net

 

 

 

1,943

 

 

 

1,777

 

Reinsurance recoverables

 

 

 

7,514

 

 

 

6,256

 

Deferred policy acquisition costs

 

 

 

1,221

 

 

 

1,198

 

Property and equipment

 

 

 

1,109

 

 

 

1,120

 

Deferred income taxes, net

 

 

 

284

 

 

 

374

 

Goodwill

 

 

 

5,990

 

 

 

6,001

 

Other assets, including other intangibles

 

 

 

2,846

 

 

 

2,355

 

Separate account assets

 

 

 

7,950

 

 

 

7,757

 

Total assets

 

 

 

$

54,939

 

 

 

$

53,734

 

Liabilities

 

 

 

 

 

 

 

 

 

Contractholder deposit funds

 

 

 

$

8,512

 

 

 

$

8,508

 

Future policy benefits

 

 

 

9,538

 

 

 

9,265

 

Unpaid claims and claim expenses

 

 

 

4,218

 

 

 

4,062

 

Global Health Care medical claims payable

 

 

 

2,000

 

 

 

1,856

 

Unearned premiums and fees

 

 

 

577

 

 

 

549

 

Total insurance and contractholder liabilities

 

 

 

24,845

 

 

 

24,240

 

Accounts payable, accrued expenses and other liabilities

 

 

 

6,976

 

 

 

6,667

 

Short-term debt

 

 

 

400

 

 

 

201

 

Long-term debt

 

 

 

4,995

 

 

 

4,986

 

Separate account liabilities

 

 

 

7,950

 

 

 

7,757

 

Total liabilities

 

 

 

45,166

 

 

 

43,851

 

Contingencies — Note 17

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interest

 

 

 

113

 

 

 

114

 

Shareholders’ Equity

 

 

 

 

 

 

 

 

 

Common stock (par value per share, $0.25; shares issued, 366; authorized, 600)

 

 

 

92

 

 

 

92

 

Additional paid-in capital

 

 

 

3,305

 

 

 

3,295

 

Net unrealized appreciation, fixed maturities

 

$

811

 

 

 

$

883

 

 

 

Net unrealized appreciation, equity securities

 

6

 

 

 

4

 

 

 

Net unrealized depreciation, derivatives

 

(25)

 

 

 

(28)

 

 

 

Net translation of foreign currencies

 

11

 

 

 

69

 

 

 

Postretirement benefits liability adjustment

 

(1,559)

 

 

 

(1,599)

 

 

 

Accumulated other comprehensive loss

 

 

 

(756)

 

 

 

(671)

 

Retained earnings

 

 

 

12,328

 

 

 

12,330

 

Less treasury stock, at cost

 

 

 

(5,309)

 

 

 

(5,277)

 

Total shareholders’ equity

 

 

 

9,660

 

 

 

9,769

 

Total liabilities and equity

 

 

 

$

54,939

 

 

 

$

53,734

 

Shareholders’ Equity Per Share

 

 

 

$

33.79

 

 

 

$

34.18

 

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

 

3



Table of Contents

 

Cigna Corporation

Consolidated Statements of Changes in Total Equity

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

Unaudited

 

 

 

Additional

 

Other

 

 

 

 

 

 

 

Redeemable

 

For the three months ended March 31, 2013

Common

 

Paid-in

 

Comprehensive

 

Retained

 

Treasury

 

Shareholders’

 

Noncontrolling

 

(In millions, except per share amounts)

 

Stock

 

Capital

 

Loss

 

Earnings

 

Stock

 

Equity

 

Interest

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at January 1, 2013

 

$

92

 

$

3,295

 

$

(671)

 

 $

12,330

 

$

(5,277)

 

$

9,769

 

$

114

 

Effect of issuing stock for employee benefit plans

 

 

 

10

 

 

 

(48)

 

65

 

27

 

 

 

Other comprehensive loss

 

 

 

 

 

(85)

 

 

 

 

 

(85)

 

(3)

 

Net income

 

 

 

 

 

 

 

57

 

 

 

57

 

2

 

Common dividends declared (per share: $0.04)

 

 

 

 

 

 

 

(11)

 

 

 

(11)

 

 

 

Repurchase of common stock

 

 

 

 

 

 

 

 

 

(97)

 

(97)

 

 

 

Balance at March 31, 2013

 

$

92

 

$

3,305

 

$

(756)

 

 $

12,328

 

$

(5,309)

 

$

9,660

 

$

113

 

 

 

 

For the three months ended March 31, 2012
(In millions, except per share amounts)

Common
Stock

 

Additional
Paid-in
Capital

 

Accumulated
Other
Comprehensive
Loss

 

Retained
Earnings

 

Treasury
Stock

 

Shareholders’
Equity

 

Redeemable
Noncontrolling
Interest

 

Balance at January 1, 2012

 

$

92

 

$

3,188

 

$

(787)

 

 $

10,787

 

$

(5,286)

 

$

7,994

 

$

 

 

Effect of issuing stock for employee benefit plans

 

 

 

80

 

 

 

(24)

 

86

 

142

 

 

 

Other comprehensive income

 

 

 

 

 

65

 

 

 

 

 

65

 

 

 

Net income

 

 

 

 

 

 

 

371

 

 

 

371

 

 

 

Common dividends declared (per share: $0.04)

 

 

 

 

 

 

 

(11)

 

 

 

(11)

 

 

 

Repurchase of common stock

 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

Balance at March 31, 2012

 

$

92

 

$

3,268

 

$

(722)

 

 $

11,123

 

$

(5,200

)

$

8,561

 

$

 

 

 

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

 

4



Table of Contents

 

Cigna Corporation

Consolidated Statements of Cash Flows

 

 

 

 

Unaudited

 

 

 

Three Months Ended
March 31,

 

(In millions)

 

2013

 

 

2012

 

Cash Flows from Operating Activities

 

 

 

 

 

 

Net income

 

$

59

 

 

$

371

 

Adjustments to reconcile net income to net cash (used in) / provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

150

 

 

126

 

Realized investment gains

 

(139)

 

 

(13)

 

Deferred income taxes

 

116

 

 

46

 

Gains on sale of businesses

 

(4)

 

 

(5)

 

Net changes in assets and liabilities, net of non-operating effects:

 

 

 

 

 

 

Premiums, accounts and notes receivable

 

(158)

 

 

(215)

 

Reinsurance recoverables

 

328

 

 

(30)

 

Deferred policy acquisition costs

 

(82)

 

 

(47)

 

Other assets

 

103

 

 

155

 

Insurance liabilities

 

750

 

 

637

 

Accounts payable, accrued expenses and other liabilities

 

(328)

 

 

(166)

 

Current income taxes

 

(110)

 

 

105

 

Cash used to effectively exit run-off reinsurance business

 

(1,475)

 

 

-

 

Other, net

 

(15)

 

 

(23)

 

Net cash (used in) / provided by operating activities

 

(805)

 

 

941

 

Cash Flows from Investing Activities

 

 

 

 

 

 

Proceeds from investments sold:

 

 

 

 

 

 

Fixed maturities

 

958

 

 

221

 

Equity securities

 

3

 

 

-

 

Commercial mortgage loans

 

46

 

 

165

 

Other (primarily short-term and other long-term investments)

 

221

 

 

300

 

Investment maturities and repayments:

 

 

 

 

 

 

Fixed maturities

 

386

 

 

317

 

Equity securities

 

9

 

 

-

 

Commercial mortgage loans

 

9

 

 

36

 

Investments purchased:

 

 

 

 

 

 

Fixed maturities

 

(383)

 

 

(831)

 

Equity securities

 

(27)

 

 

-

 

Commercial mortgage loans

 

(15)

 

 

(180)

 

Other (primarily short-term and other long-term investments)

 

(121)

 

 

(167)

 

Property and equipment purchases

 

(84)

 

 

(81)

 

Acquisitions and dispositions, net of cash acquired

 

(40)

 

 

(3,199)

 

Net cash provided by / (used in) investing activities

 

962

 

 

(3,419)

 

Cash Flows from Financing Activities

 

 

 

 

 

 

Deposits and interest credited to contractholder deposit funds

 

363

 

 

261

 

Withdrawals and benefit payments from contractholder deposit funds

 

(332)

 

 

(231)

 

Change in cash overdraft position

 

(3)

 

 

22

 

Net change in short-term debt

 

198

 

 

123

 

Repayment of long-term debt

 

-

 

 

(326)

 

Repurchase of common stock

 

(77)

 

 

-

 

Issuance of common stock

 

36

 

 

45

 

Net cash provided by / (used in) financing activities

 

185

 

 

(106)

 

Effect of foreign currency rate changes on cash and cash equivalents

 

(14)

 

 

5

 

Net increase / (decrease) in cash and cash equivalents

 

328

 

 

(2,579)

 

Cash and cash equivalents, January 1,

 

2,978

 

 

4,690

 

Cash and cash equivalents, March 31,

 

$

3,306

 

 

$

2,111

 

Supplemental Disclosure of Cash Information:

 

 

 

 

 

 

Income taxes paid, net of refunds

 

$

12

 

 

$

22

 

Interest paid

 

$

70

 

 

$

54

 

 

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

 

5



Table of Contents

 

CIGNA CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

 

Note 1 — Basis of Presentation

 

 

Cigna Corporation was incorporated in the State of Delaware in 1981. Various businesses that are described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (“2012 Form 10-K”) are conducted by its insurance and other subsidiaries.  As used in this document, “Cigna”, the “Company”, “we” and  “our” may refer to Cigna Corporation itself, one or more of its subsidiaries, or Cigna Corporation and its consolidated subsidiaries.  The Consolidated Financial Statements include the accounts of Cigna Corporation and its significant subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation.  These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

The Company is a global health services organization with a mission to help its customers improve their health, well-being and sense of security.  Its insurance subsidiaries are major providers of medical, dental, disability, life and accident insurance and related products and services,  the majority of which are offered through employers and other groups (e.g. governmental and non-governmental organizations, unions and associations). Cigna also offers Medicare and Medicaid products and health, life and accident insurance coverages primarily to individuals in the U.S. and selected international markets.  In addition to its ongoing operations described above, the Company also has certain run-off operations, including a Run-off Reinsurance segment.

 

The interim consolidated financial statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported.  The interim consolidated financial statements and notes should be read in conjunction with the Consolidated Financial Statements and Notes in the Company’s 2012 Form 10-K.

 

The preparation of interim consolidated financial statements necessarily relies heavily on estimates.  This and certain other factors, such as the seasonal nature of portions of the health care and related benefits business as well as competitive and other market conditions, call for caution in estimating full year results based on interim results of operations. Certain reclassifications have been made to prior period amounts to conform to the current presentation.  In particular, as a result of the changes in segment reporting discussed further in Note 16, benefits expense amounts previously reported in Other Benefits Expense for the international health care business have been reclassified to Global Health Care Medical Claims Expense in the Consolidated Statement of Income for the three months ended March 31, 2012.

 

Note 2 — Recent Accounting Pronouncements

 

 

Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“AOCI”) (Accounting Standards Update (“ASU”) 2013-02).   Effective January 1, 2013, the Company adopted the Financial Accounting Standards Board’s (“FASB”) updated guidance on the reporting of items of AOCI reclassified to net income.  The updated guidance requires disclosures of the effect of items reclassified out of AOCI into net income on each individual line item in the statement of income.  See Note 14 for the Company’s updated disclosures.

 

Disclosures about Offsetting Assets and Liabilities (ASU 2011-11).  The FASB’s new requirements to disclose information on both a gross and net basis for certain derivatives, repurchase and reverse repurchase agreements, and securities borrowing and lending transactions that are either offset in accordance with specific criteria or subject to a master netting or similar arrangement became effective January 1, 2013.   There were no effects to the Company’s financial statements because no transactions or arrangements were subject to these new disclosure requirements.

 

Fees Paid to the Federal Government by Health Insurers (ASU 2011-06).  In 2011, the FASB issued accounting guidance for the health insurance industry assessment  (the “fee”) mandated by the Patient Protection and Affordable Care Act of 2010 (“Health Care Reform”).  The fee will be levied on health insurers beginning in 2014 based on a ratio of an insurer’s net health insurance premiums written for the previous calendar year compared to the U.S. health insurance industry total. In addition, because these fees will generally not be tax deductible, the Company’s effective tax rate is expected to be adversely impacted in future periods.  Under the guidance, the liability for the fee will be estimated and recorded in full each year beginning in 2014 when health insurance is first provided.  A corresponding deferred cost will be recorded and amortized over the calendar year.  The amount of the fees is expected to be material, although the Company is unable to estimate the impact of these fees on shareholders’ net income and the effective tax rate.

 

6



Table of Contents

 

Note 3  Acquisitions and Dispositions

 

 

The Company may from time to time acquire or dispose of assets, subsidiaries or lines of business.  For further information on the effective exit from the guaranteed minimum death benefits (“GMDB”) and guaranteed minimum income benefits (“GMIB”) business, see Note 6. Other significant transactions are described below.

 

A. Joint Venture Agreement with Finansbank

 

On November 9, 2012, the Company acquired 51% of the total shares of Finans Emeklilik ve Hayat A.S. (“Finans Emeklilik”), a Turkish insurance company, from Finansbank A.S. (“Finansbank”), a Turkish retail bank, for a cash purchase price of approximately $116 million. Finansbank continues to hold 49% of the total shares. Finans Emeklilik operates in life insurance, accident insurance and pension product markets. The acquisition provides Cigna opportunities to reach and serve the growing middle class market in Turkey through Finansbank’s network of retail banking branches.

 

In accordance with GAAP, the total purchase price, including the redeemable noncontrolling interest of $111 million, has been allocated to the tangible and intangible net assets acquired based on management’s estimates of their fair value. Accordingly, approximately $113 million was allocated to identifiable intangible assets, primarily a distribution relationship and the value of business acquired (“VOBA”) that represents the present value of the estimated net cash flows from the long duration contracts in force, with the remaining $116 million recorded as goodwill.  The identifiable intangible assets will be amortized over an estimated useful life of approximately 10 years.   Goodwill has been allocated to the Global Supplemental Benefits segment and is not deductible for federal income tax purposes.

 

The redeemable noncontrolling interest is classified as temporary equity in the Company’s Consolidated Balance Sheet because Finansbank has the right to require the Company to purchase its 49% interest for the value of its net assets and the inforce business in 15 years.

 

The condensed balance sheet at the acquisition date was as follows:

 

(In millions)

 

 

 

Investments

 

$

23

 

Cash and cash equivalents

 

54

 

Value of business acquired (reported in Deferred policy acquisition costs in the Consolidated Balance Sheet)

 

26

 

Goodwill

 

116

 

Separate account assets

 

99

 

Other assets, including other intangibles

 

98

 

Total assets acquired

 

416

 

Insurance liabilities

 

58

 

Accounts payable, accrued expenses and other liabilities

 

32

 

Separate account liabilities

 

99

 

Total liabilities acquired

 

189

 

Redeemable noncontrolling interest

 

111

 

Net assets acquired

 

$

116

 

 

The results of Finans Emeklilik have been included in the Company’s Consolidated Financial Statements from the date of acquisition.  The pro forma effects on total revenues and net income assuming the acquisition had occurred as of January 1, 2012 were not material to the Company for the three months ended March 31, 2012.

 

7



Table of Contents

 

B. Acquisition of Great American Supplemental Benefits Group

 

On August 31, 2012, the Company acquired Great American Supplemental Benefits Group, one of the largest providers of supplemental health insurance products in the U.S. for $326 million, with cash from internal sources.  The acquisition provides the Company with an increased presence in the Medicare supplemental benefits market. It also extends the Company’s global direct-to-consumer retail channel as well as further enhances its distribution network of agents and brokers. Subsequent to the segment reporting changes in 2012, results of this business are reported in the Global Supplemental Benefits segment.

 

In accordance with GAAP, the total purchase price has been allocated to the tangible and intangible net assets acquired based on management’s estimates of their fair value.  Approximately $168 million was allocated to intangible assets, primarily the VOBA asset that will be amortized in proportion to premium recognized over the life of the contracts that is estimated to be 30 years. Amortization will be higher in early years and decline as policies lapse. Goodwill has been allocated to the Global Supplemental Benefits segment.  Substantially all of the goodwill is tax deductible and will be amortized over the next 15 years for federal income tax purposes.

 

The condensed balance sheet at the acquisition date was as follows:

 

(In millions)

 

 

 

Investments

$

211

 

Cash and cash equivalents

 

36

 

Reinsurance recoverables

 

448

 

Goodwill

 

168

 

Value of business acquired (reported in Deferred policy acquisition costs in the Consolidated Balance Sheet)

 

144

 

Other assets, including other intangibles

 

35

 

  Total assets acquired

 

1,042

 

Insurance liabilities

 

707

 

Accounts payable, accrued expenses and other liabilities

 

9

 

  Total liabilities acquired

 

716

 

Net assets acquired

$

326

 

 

The results of Great American Supplemental Benefits have been included in the Company’s Consolidated Financial Statements from the date of acquisition.  The pro forma effects on total revenues and net income assuming the acquisition had occurred as of January 1, 2012 were not material to the Company for the three months ended March 31, 2012.

 

C. Acquisition of HealthSpring, Inc.

 

On January 31, 2012 the Company acquired the outstanding shares of HealthSpring, Inc. (“HealthSpring”) for $55 per share in cash and Cigna stock awards, representing a cost of approximately $3.8 billion.  HealthSpring provides Medicare Advantage coverage in 15 states and the District of Columbia, as well as a large, national stand-alone Medicare prescription drug business.  The acquisition of HealthSpring strengthens the Company’s ability to serve individuals across their life stages as well as deepens its presence in a number of geographic markets. The addition of HealthSpring brings industry leading physician partnership capabilities and creates the opportunity to deepen the Company’s existing client and customer relationships, as well as facilitates a broader deployment of its range of health and wellness capabilities and product offerings. The Company funded the acquisition with internal cash resources.

 

8



Table of Contents

 

Purchase price allocation. In accordance with GAAP, the total purchase price has been allocated to the tangible and intangible net assets acquired based on management’s estimates of their fair values. Goodwill is not deductible for federal income tax purposes and is allocated to the Government operating segment.  The condensed balance sheet of HealthSpring at the acquisition date was as follows:

 

(In millions)

 

 

 

Investments

 

$

612

 

Cash and cash equivalents

 

492

 

Premiums, accounts and notes receivable

 

320

 

Goodwill

 

2,541

 

Intangible assets

 

795

 

Other

 

96

 

Total assets acquired

 

4,856

 

Insurance liabilities

 

505

 

Deferred income taxes

 

214

 

Debt

 

326

 

Total liabilities acquired

 

1,045

 

Net assets acquired

 

$

3,811

 

 

In accordance with debt covenants, HealthSpring’s debt obligation was paid immediately following the acquisition.  This repayment is reported as a financing activity in the statement of cash flows for the three months ended March 31, 2012.

 

The results of HealthSpring have been included in the Company’s Consolidated Financial Statements from the date of the acquisition.  Revenues of HealthSpring included in the Company’s results for the three months ended March 31, 2012 were approximately $1.0 billion.

 

Pro forma information.  The following table presents selected unaudited pro forma information for the Company assuming the acquisition of HealthSpring had occurred as of January 1, 2011.  This pro forma information does not purport to represent what the Company’s actual results would have been if the acquisition had occurred as of the date indicated or what such results would be for any future periods.

 

 

 

Three Months Ended

 

(In millions, except per share amounts)

 

March 31, 2012

 

Total revenues

 

$

7,277

 

Shareholders’ net income

 

$

381

 

Earnings per share:

 

 

 

Basic

 

$

1.33

 

Diluted

 

$

1.32

 

 

9



Table of Contents

 

Note 4 Earnings Per Share (“EPS”)

 

 

Basic and diluted earnings per share were computed as follows:

 

 

 

 

 

Effect of

 

 

 

(Dollars in millions, except per share amounts)

 

Basic

 

Dilution

 

Diluted

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2013 

 

 

 

 

 

 

 

Shareholders’ net income

 

$

57

 

 

 

$

57

 

Shares (in thousands):

 

 

 

 

 

 

 

Weighted average

 

283,804

 

 

 

283,804

 

Common stock equivalents

 

 

 

5,454

 

5,454

 

Total shares

 

283,804

 

5,454

 

289,258

 

EPS

 

$

0.20

 

$

-

 

$

0.20

 

2012 

 

 

 

 

 

 

 

Shareholders’ net income

 

$

371

 

 

 

$

371

 

Shares (in thousands):

 

 

 

 

 

 

 

Weighted average

 

285,159

 

 

 

285,159

 

Common stock equivalents

 

 

 

3,840

 

3,840

 

Total shares

 

285,159

 

3,840

 

288,999

 

EPS

 

$

1.30

 

$

(0.02)

 

$

1.28

 

 

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect would have increased diluted earnings per share (antidilutive) as their exercise price was greater than the average share price of the Company’s common stock for the period.

 

 

 

Three Months Ended

 

 

 

March 31,

 

(In millions)

 

2013

 

 

2012

 

Antidilutive options

 

-

 

 

3.8

 

 

The Company held 80,302,892 shares of common stock in Treasury as of March 31, 2013, and 77,847,260 shares as of March 31, 2012.

 

Note 5 Global Health Care Medical Claims Payable

 

 

Medical claims payable for the Global Health Care segment reflects estimates of the ultimate cost of claims that have been incurred but not yet reported, those that have been reported but not yet paid (reported claims in process), and other medical expenses payable that is primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. The liability for incurred but not yet reported claims is the majority of the reserve balance as follows:

 

 

 

March 31,

 

December 31,

 

(In millions)

 

2013

 

2012

 

Incurred but not yet reported

 

$

1,717

 

$

1,541

 

Reported claims in process

 

190

 

243

 

Physician incentives and other medical expense payable

 

93

 

72

 

Medical claims payable

 

$

2,000

 

$

1,856

 

 

10



Table of Contents

 

Activity in medical claims payable was as follows:

 

 

 

For the period ended

 

 

 

March 31,

 

December 31,

 

(In millions)

 

2013

 

2012

 

Balance at January 1,

 

$

1,856

 

$

1,305

 

Less: Reinsurance and other amounts recoverable

 

242

 

249

 

Balance at January 1, net

 

1,614

 

1,056

 

 

 

 

 

 

 

Acquired net:

 

-

 

504

 

Incurred claims related to:

 

 

 

 

 

Current year

 

4,164

 

14,428

 

Prior years

 

(117)

 

(200)

 

Total incurred

 

4,047

 

14,228

 

Paid claims related to:

 

 

 

 

 

Current year

 

2,694

 

12,854

 

Prior years

 

1,162

 

1,320

 

Total paid

 

3,856

 

14,174

 

Ending Balance, net

 

1,805

 

1,614

 

Add: Reinsurance and other amounts recoverable

 

195

 

242

 

Ending Balance

 

$

2,000

 

$

1,856

 

 

Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims for minimum premium products and certain administrative services only business where the right of offset does not exist.  See Note 6 for additional information on reinsurance.  For the three months ended March 31, 2013, actual experience differed from the Company’s key assumptions resulting in favorable incurred claims related to prior years’ medical claims payable of $117 million, or 0.8% of the current year incurred claims as reported for the year ended December 31, 2012. Actual completion factors accounted for $47 million, or 0.3% of the favorability while actual medical cost trend resulted in the remaining $70 million, or 0.5%.

 

For the year ended December 31, 2012, actual experience differed from the Company’s key assumptions, resulting in favorable incurred claims related to prior years’ medical claims payable of $200 million, or 2.2% of the current year incurred claims as reported for the year ended December 31, 2011. Actual completion factors accounted for $91 million, or 1.0% of favorability while actual medical cost trend resulted in the remaining $109 million, or 1.2%.

 

The impact of prior year development on shareholders’ net income was $48 million for the three months ended March 31, 2013 compared with $41 million for the three months ended March 31, 2012.  The favorable effect of prior year development for both years primarily reflects low utilization of medical services, as well as the impact of the medical loss ratio (MLR) rebate accrual.  The change in the amount of the incurred claims related to prior years in the medical claims payable liability does not directly correspond to an increase or decrease in the Company’s shareholders’ net income recognized for the following reasons:

 

First, the Company consistently recognizes the actuarial best estimate of the ultimate liability within a level of confidence, as required by actuarial standards of practice that require the liabilities be adequate under moderately adverse conditions. As the Company establishes the liability for each incurral year, the Company ensures that its assumptions appropriately consider moderately adverse conditions. When a portion of the development related to the prior year incurred claims is offset by an increase determined appropriate to address moderately adverse conditions for the current year incurred claims, the Company does not consider that offset amount as having any impact on shareholders’ net income.

 

Second, as a result of the MLR provisions of the Patient Protection and Affordable Care Act, changes in medical claim estimates due to prior year development may be offset by a change in the MLR rebate accrual.

 

11



Table of Contents

 

Third, changes in reserves for the Company’s retrospectively experience-rated business do not always impact shareholders’ net income.  For the Company’s retrospectively experience-rated business only adjustments to medical claims payable on accounts in deficit affect shareholders’ net income. An increase or decrease to medical claims payable on accounts in deficit, in effect, accrues to the Company and directly impacts shareholders’ net income. An account is in deficit when the accumulated medical costs and administrative charges, including profit charges, exceed the accumulated premium received. Adjustments to medical claims payable on accounts in surplus generally accrue directly to the policyholder with no impact on the Company’s shareholders’ net income. An account is in surplus when the accumulated premium received exceeds the accumulated medical costs and administrative charges, including profit charges.

 

The determination of liabilities for Global Health Care medical claims payable requires the Company to make critical accounting estimates. See Note 2(N) to the Consolidated Financial Statements in the Company’s 2012 Form 10-K.

 

Note 6 — Reinsurance

 

The Company’s insurance subsidiaries enter into agreements with other insurance companies to assume and cede reinsurance.  Reinsurance is ceded primarily to limit losses from large exposures and to permit recovery of a portion of direct losses.  Reinsurance is also used in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability.  The Company regularly evaluates the financial condition of its reinsurers and monitors its concentrations of credit risk.

 

Effective Exit of GMDB and GMIB Business

 

On February 4, 2013, the Company entered into an agreement with Berkshire Hathaway Life Insurance Company of Nebraska (Berkshire) to effectively exit the GMDB and GMIB business via a reinsurance transaction.  Berkshire reinsured 100% of the Company’s future claim payments, net of retrocessional arrangements in place prior to February 4, 2013.  The reinsurance agreement is subject to an overall limit of approximately $3.8 billion plus future premiums collected under the contracts being reinsured that will be paid to Berkshire.  The Company estimates that these future premium amounts will be from $0.1 to $0.3 billion and, accordingly, expects future claims of approximately $4 billion to be covered by the agreement.

 

This transaction resulted in an after-tax charge to shareholders’ net income in the first quarter of 2013 of $507 million ($781 million pre-tax reported as follows:  $727 million in other benefits expense; $45 million in GMIB fair value (gain) loss; and $9 million in other operating expenses). The reinsurance premium due to Berkshire under the agreement was $2.2 billion, of which $1.5 billion was paid through March 31, 2013.  The unpaid premium of $0.7 billion as of March 31, 2013 is included in Accounts payable, accrued expenses and other liabilities in the Consolidated Balance Sheet and was paid on April 18, 2013.  The reinsurance premium was funded from the sale of investment assets, tax benefits related to the transaction and available parent cash.

 

Recoverables for GMDB and GMIB Business

 

The Company had reinsurance recoverables related to the GMDB business of approximately $1.4 billion and GMIB assets of $1.1 billion as of March 31, 2013. Approximately 80% of the combined GMDB recoverables and GMIB assets of $2.5 billion are secured by assets in trust, letters of credit, or funds withheld or are not subject to collection risk.  Approximately $1.8 billion of the combined GMDB recoverables and GMIB assets relate to the February 4, 2013 reinsurance arrangement with Berkshire, including $0.7 billion for the cost of reinsurance (excess of premium over recorded reserves).

 

The following disclosures for the reinsured GMDB and GMIB business provide further context to prior year results as well as activity in the assets and liabilities including the impacts of the reinsurance transaction.

 

GMDB

 

The Company has historically estimated its liabilities for assumed and ceded GMDB exposures with an internal model using many scenarios and based on assumptions regarding lapse, future partial surrenders, claim mortality (deaths that result in claims), interest rates (mean investment performance and discount rate) and volatility.  These assumptions are based on the Company’s experience and future expectations over an extended period, consistent with the long-term nature of this product.

 

In 2000, the Company determined that the GMDB reinsurance business was premium deficient because the recorded future policy benefit reserve was less than the expected present value of future claims and expenses less the expected present value of future premiums and investment income using revised assumptions based on actual and expected experience.  The Company tests for premium deficiency by reviewing its reserve each quarter using current market conditions and its long-term assumptions.  Under

 

12



Table of Contents

 

premium deficiency accounting, if the recorded reserve is determined insufficient, an increase to the reserve is reflected as a charge to current period income. The premium attributable to GMDB from the reinsurance transaction with Berkshire was approximately $1.6 billion.  Because this premium exceeded the recorded reserve on February 4, 2013, the Company recorded a reserve strengthening of $0.7 billion ($0.5 billion after-tax) in the first quarter of 2013.  Subsequent to the reinsurance transaction on February 4, 2013, any such reserve increase will have a corresponding increase in the recorded reinsurance recoverable, provided that the increased recoverable remains within the overall limit (including the GMIB asset).

 

The Company’s dynamic hedge programs were discontinued during the first quarter of 2013 due to the reinsurance agreement with Berkshire.  These programs were used to reduce certain equity and interest rate exposures associated with this business. These hedge programs generated losses of $32 million for the three months ended March 31, 2013 and $87 million for the three months ended March 31, 2012 that were  included in Other Revenues.  Prior to the hedge programs being discontinued, amounts representing corresponding reductions in liabilities for GMDB contracts were included in benefits and expenses.  As a result of discontinuing the hedge programs, the growth rate assumption for the underlying equity funds was changed to use long-term historical averages, resulting in a decrease in the gross reserve liability and the offsetting reinsurance recoverable.

 

For the full year ended December 31, 2012, a reserve strengthening of $43 million ($27 million after-tax) was due primarily to reductions to the lapse rate assumptions, adverse interest rate impacts, and, to a lesser extent, an increase in the volatility and correlation assumptions, partially offset by favorable equity market conditions.  The adverse interest rate impacts reflect management’s consideration of the anticipated impact of continued low short-term interest rates.

 

Activity in future policy benefit reserves for the GMDB business was as follows:

 

 

 

For the period ended

 

 

 

March 31,

 

December 31,

 

(In millions)

 

2013

 

2012

 

Balance at January 1

 

$

1,090

 

$

1,170

 

Add: Unpaid claims

 

24

 

40

 

Less: Reinsurance and other amounts recoverable

 

42

 

53

 

Balance at January 1, net

 

1,072

 

1,157

 

Add: Incurred benefits

 

702

 

17

 

Less: Paid benefits (including $1,647 premium for Berkshire)

 

1,672

 

102

 

Ending balance, net

 

102

 

1,072

 

Less: Unpaid claims

 

23

 

24

 

Add: Reinsurance and other amounts recoverable

 

1,371

 

42

 

Ending balance

 

$

1,450

 

$

1,090

 

 

Benefits paid and incurred are net of ceded amounts.  For the three months ended March 31, 2013, incurred benefits reflect the February 4, 2013 reinsurance transaction.  The remaining retained reserve in 2013 is to cover claims retained by the Company, as well as ongoing administrative expenses.  Incurred benefits reflect the favorable or unfavorable impact of a rising or falling equity market on the liability, and include the charges discussed above.

 

The death benefit coverage in force for GMDB contracts assumed by the Company (and reinsured as of February 4, 2013) was $3.6 billion as of March 31, 2013 and $4 billion as of December 31, 2012.  The death benefit coverage in force represents the excess of the guaranteed benefit amount over the value of the underlying mutual fund investments for all contractholders (approximately 425,000 as of March 31, 2013 and 435,000 as of December 31, 2012). The aggregate value of the underlying mutual fund investments for these GMDB contracts, assuming no reinsurance, was $13.7 billion as of March 31, 2013 and $13.3 billion as of December 31, 2012.

 

GMIB

 

As discussed further in Note 8, because GMIB contracts are without significant life insurance risk, they are not accounted for as insurance products. Instead, the Company reports GMIB liabilities and assets as derivatives at fair value. The GMIB asset is classified in Other assets, including other intangibles and the GMIB liability is classified in Accounts payable, accrued expenses and other liabilities in the Consolidated Balance Sheet.  Disclosures related to fair value are included in Note 8 and the derivative is further described under Note 10.

 

The February 4, 2013 transaction with Berkshire described above resulted in an increase in GMIB assets, representing the increased

 

13



Table of Contents

 

receivable from that transaction. As of March 31, 2013, GMIB assets include $0.5 billion from Berkshire.

 

In addition, the GMIB business had GMIB assets of $0.6 billion (classified in Other assets, including other intangibles in the Consolidated Balance Sheet) from two other retrocessionaires as of March 31, 2013.

 

Other Run-off

 

The Company’s Run-off Reinsurance operations also assumed risks related to workers’ compensation and personal accident business, and purchased retrocessional coverage to reduce the risk of loss on these contracts.  The reinsurance recoverables were $125 million as of March 31, 2013.  Of this amount, approximately 99% are secured by assets in a trust or letters of credit.

 

Other Reinsurance

 

Supplemental benefits business. The Company had reinsurance recoverables of approximately $394 million as of March 31, 2013 and $402 million as of December 31, 2012 from Great American Life Insurance Company resulting from the acquisition of Great American’s Supplemental Benefits business on August 31, 2012. The life insurance and annuity lines of business written by the acquired legal entities were fully reinsured by the seller as part of the transaction. The resulting reinsurance recoverables are secured primarily by fixed maturities with book value equal to or greater than 100% of the reinsured policy liabilities. These fixed maturities are held in a trust established for the benefit of the Company.

 

Retirement benefits business.  The Company had reinsurance recoverables of $1.3 billion as of March 31, 2013 and December 31, 2012 from Prudential Retirement Insurance and Annuity Company resulting from the sale of the retirement benefits business, that was primarily in the form of a reinsurance arrangement.  The reinsurance recoverable, that is reduced as the Company’s reinsured liabilities are paid or directly assumed by the reinsurer, is secured primarily by fixed maturities whose book value is equal to or greater than 100% of the reinsured liabilities.  These fixed maturities are held in a trust established for the benefit of the Company.  As of March 31, 2013, the book value of the trust assets exceeded the recoverable.

 

Individual life and annuity reinsurance. The Company had reinsurance recoverables of $4 billion as of March 31, 2013 and December 31, 2012 from The Lincoln National Life Insurance Company and Lincoln Life & Annuity of New York resulting from the 1998 sale of the Company’s individual life insurance and annuity business through indemnity reinsurance arrangements.  The Lincoln National Life Insurance Company and Lincoln Life & Annuity of New York must maintain a specified minimum credit or claims paying rating, or they will be required to fully secure the outstanding balance.  As of March 31, 2013, both companies had ratings sufficient to avoid triggering this contractual obligation.

 

Ceded Reinsurance: Ongoing operations. The Company’s insurance subsidiaries have reinsurance recoverables from various reinsurance arrangements in the ordinary course of business for its Global Health Care, Global Supplemental Benefits and Group Disability and Life segments as well as the non-leveraged and leveraged corporate-owned life insurance business.  Reinsurance recoverables of $346 million as of March 31, 2013 are expected to be collected from more than 80 reinsurers.

 

The Company reviews its reinsurance arrangements and establishes reserves against the recoverables in the event that recovery is not considered probable. As of March 31, 2013, the Company’s recoverables related to these segments were net of a reserve of $3 million.

 

Summary. The Company’s reserves for underlying reinsurance exposures assumed by the Company, as well as for amounts recoverable from reinsurers and retrocessionaires for both ongoing operations and the run-off reinsurance operation, are considered appropriate as of March 31, 2013, based on current information.  The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company.

 

14



Table of Contents

 

Effects of reinsuranceIn the Company’s Consolidated Statements of Income, Premiums and fees were net of ceded premiums, and Total benefits and expenses were net of reinsurance recoveries, in the following amounts:

 

 

 

Three Months Ended

 

 

 

March 31,

 

(In millions)

 

2013

 

2012

 

Ceded premiums and fees

 

 

 

 

 

Individual life insurance and annuity business sold

 

$

46

 

$

51

 

Other

 

79

 

66

 

Total

 

$

125

 

$

117

 

Reinsurance recoveries

 

 

 

 

 

Individual life insurance and annuity business sold

 

$

88

 

$

68

 

Other

 

(262)

 

54

 

Total

 

$

(174)

 

$

122

 

 

As noted in the GMDB section above, recoveries for the three months ended March 31, 2013 are net of the impact of a decrease in reinsurance recoverables due to a change in the growth rate assumption, resulting from the discontinuance of the hedge programs following the reinsurance transaction with Berkshire.

 

Note 7 — Realignment and Efficiency Plan

 

 

During the third quarter of 2012, in connection with the execution of its strategy, the Company committed to a series of actions to further improve its organizational alignment, operational effectiveness, and efficiency.  As a result, the Company recognized charges in other operating expenses of $77 million pre-tax ($50 million after-tax) in the third quarter of 2012 consisting primarily of severance costs.  Summarized below is activity in the liability for the three months ended March 31, 2013:

 

(In millions)

 

Severance

 

Real estate

 

Total

 

Balance, January 1, 2013

 

$

67

 

$

4

 

$

71

 

Less: Payments

 

8

 

1

 

9

 

Balance, March 31, 2013

 

$

59

 

$

3

 

$

62

 

 

The severance costs are expected to be substantially paid in 2013.

 

Note 8 Fair Value Measurements

 

 

The Company carries certain financial instruments at fair value in the financial statements including fixed maturities, equity securities, short-term investments and derivatives.  Other financial instruments are measured at fair value under certain conditions, such as when impaired.

 

Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date.  A liability’s fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.

 

The Company’s financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP.  The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset’s or a liability’s classification is based on the lowest level of input that is significant to its measurement.  For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument’s fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

 

15



Table of Contents

 

The Company estimates fair values using prices from third parties or internal pricing methods.  Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available, and other market information that a market participant may use to estimate fair value.  The internal pricing methods are performed by the Company’s investment professionals, and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality, as well as other qualitative factors.  In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price.  These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.

 

The Company is responsible for determining fair value, as well as the appropriate level within the fair value hierarchy, based on the significance of unobservable inputs.   The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates.  The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value.  The controls completed by the Company and third-party pricing services include reviewing to ensure that prices do not become stale and whether changes from prior valuations are reasonable or require additional review.  The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates.  Exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations.

 

 

Financial Assets and Financial Liabilities Carried at Fair Value

 

The following tables provide information as of March 31, 2013 and December 31, 2012 about the Company’s financial assets and liabilities carried at fair value.  Similar disclosures for separate account assets, which are also recorded at fair value on the Company’s Consolidated Balance Sheets, are provided separately as gains and losses related to these assets generally accrue directly to policyholders.

 

March 31, 2013
(In millions)

 

Quoted Prices in
Active Markets for
Identical Assets
(Level 1)

 

Significant Other
Observable Inputs
(Level 2)